Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2004-09-24
2008-12-23
Canella, Karen A. (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007230, C530S387100, C530S388100, C530S388800
Reexamination Certificate
active
07468254
ABSTRACT:
This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMABs of the instant invention.
REFERENCES:
patent: 4861581 (1989-08-01), Epstein et al.
patent: 4879225 (1989-11-01), Morgan et al.
patent: 5017693 (1991-05-01), Hylarides et al.
patent: 5034223 (1991-07-01), Abrams et al.
patent: 5112954 (1992-05-01), Abrams et al.
patent: 5171665 (1992-12-01), Hellstrom et al.
patent: 5270202 (1993-12-01), Raychaudhuri
patent: 5484596 (1996-01-01), Hanna, Jr. et al.
patent: 5493009 (1996-02-01), Ferrone
patent: 5580774 (1996-12-01), Beavers et al.
patent: 5693763 (1997-12-01), Codington et al.
patent: 5707603 (1998-01-01), Toner et al.
patent: 5750102 (1998-05-01), Eisenbach et al.
patent: 5780029 (1998-07-01), Ferrone
patent: 5780033 (1998-07-01), Torchilin et al.
patent: 5783186 (1998-07-01), Arakawa et al.
patent: 5817774 (1998-10-01), Delecki et al.
patent: 5849876 (1998-12-01), Linsley et al.
patent: 5869045 (1999-02-01), Hellstrom et al.
patent: 5869268 (1999-02-01), Kudo et al.
patent: 6180357 (2001-01-01), Young et al.
patent: 6238667 (2001-05-01), Kohler
patent: 6248870 (2001-06-01), Delecki et al.
patent: 2004/0141913 (2004-07-01), Young et al.
patent: 2004/0141979 (2004-07-01), Young et al.
patent: 2004/0151665 (2004-08-01), Young et al.
patent: 2004/0197328 (2004-10-01), Young et al.
patent: 2006/0019256 (2006-01-01), Clarke et al.
patent: 380607 (1994-12-01), None
patent: WO92/16646 (1992-10-01), None
patent: WO03/086456 (2003-10-01), None
Li et al. (Proc. Natl. Acad. Sci. USA, 1980 77:3211-3214).
Rudikoff et al, (PNAS, USA, 1982, 79: 1979).
Jiang et al (JBC, 2003, 278(7) 4763-4769).
Matsushita et al (FEBS Letters, 1999, vol. 443, pp. 348-352).
Singh et al (Glycobiology, 2001, vol. 11, pp. 587-592).
Freshney (Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p. 4).
Dermer (Bio/Technology, 1994, 12:320).
Drexler et al (Leukemia and Lymphoma, 1993, 9:1-25).
Zellner et al (Clin. Can. Res., 1998, 4:1797-17802).
Embleton et al (Immunol Ser, 1984, 23:181-207).
Taber's Cyclopedic Medical Dictionary (1985, F.A. Davis Company, Philadelphia, p. 274).
Busken, C et al, (Digestive Disease Week Abstracts and Itinerary Planner, 2003, abstract No. 850.
Kaiser (Science, 2006, 313, 1370).
T. Karpanen et al, “Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth”, Cancer Research, 61:1786-1790 (Mar. 2001).
W. Waud et al, “Characterization of in vivo mammary and prostate tumor xenograft models for growth and response to clinical anticancer agents”, Contrib Oncol Basel Karger, 54:305-315 (1999).
G. Klement et al, “Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts”, Clinical Cancer Research, 8:221-232 (Jan. 2002).
D. Blakey et al, “Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models”, Clinical Cancer Research, 8:1974-1983 (Jun. 2002).
Z. Xiao et al, “Generation of a baculovirus recombinant prostate-specific membrane antigen and its use in the development of a novel protein biochip quantitative immunoassay”, Protein Expresion and Purification, 19:12-21 (2000).
S. Guichard et al, “Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: pharmacokinetic and pharmacodynamic evaluation”, Clinical Cancer Research, 7:3222-3228 (Oct. 2001).
V. Von Gruenigen et al, “Efficacy of intraperitoneal adenovirus-mediated p53 gene therapy in ovarian cancer”, Int. J. Gynecol. Cancer, 9:365-372 (1999).
N. Guilbaud et al, “Marked antitumor activity of a new potent acronycine derivative in orthotopic models of human solid tumors”, Clinical Cancer Research, 7:2573-2580 (Aug. 2001).
K. Olson et al, “Inhibition of prostate carcinoma establishment and metastatic growth in mice by an antiangiogenin monoclonal antibody”, Int. J. Cancer, 98:923-929 (2002).
S. Hirschfeld et al, “Oncology drug development: United States Food and Drug Administration perspective”, Critical Reviews in Oncology/Hematology, 42:137-143 (2002).
P. Therasse et al, “New guidelines to evaluate the response to treatment in solid tumors”, Journal of the National Cancer Institute, 92(3):205-216 (Feb. 2000).
G. Eckhardt et al, “Developmental therapeutics: successes and failures of clinical trial designs of targeted compounds”, in American Society of Clinical Oncology, pp. 209-219 (2003).
P. Smith et al, “Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice”, The Prostate, 48:47-53 (2001).
T. Bumol et al, “Unique glycoprotein-proteoglycan complex defined by monoclonal antibody on human melanoma cells”, Proc. Natl. Acad. Sci. USA, 79(4):1245-1249 (Feb. 1982).
P. Chattopadhyay et al, “Murine monoclonal anti-idiotope antibody breaks unresponsiveness and induces a specific antibody response to human melanoma-associated proteoglycan antigen in cynomolgus monkeys”, Proc. Natl. Acad. Sci. USA, 89:2684-2688 (Apr. 1992).
T. Bumol et al, “Monoclonal antibody and an antibody-toxin conjugate to a cell surface proteoglycan of melanoma cells suppress in vivo tumor growth”, Proc. Natl. Acad. Sci. USA, 80(2):529-533 (Jan. 1983).
G. Pluschke et al, “Molecular cloning of a human melanoma-associated chondroitin sulfate proteoglycan”, Proc. Natl. Acad. Sci. USA, 93:9710-9715 (Sep. 1996).
J. Iida et al, “Melanoma chondroitin sulfate proteoglycan regulates matrix metalloproteinase-dependent human melanoma invasion into type I collagen”, J. Biol. Chem., 276(22):18786-18794 (Jun. 2001).
K. Eisenmann et al, “Melanoma chondroitin sulphate proteoglycan regulates cell spreading through Cdc42, Ack-1 and p130cas”, Nature Cell Biology, 1:507-513 (Dec. 1999).
S. Ferrone et al, “Human high molecular weight-melanoma asociated antigen mimicry by mouse antri-idiotypic monoclonal antibodies MK2-23 experimental studies and clinical trials in patients with malignant melanoma”, Pharmac. Ther., 57:259-290 (1993).
A. Mittelman et al, “Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma”, Proc. Natl. Acad. Sci. USA, 89:466-470 (Jan. 1992).
H. Ming Yang et al, “Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice”, Proc. Natl. Acad. Sci. USA, 85:1189-1193 (Feb. 1988).
M. Kusama et al, “Characterization of syngeneic antiidiotypic monoclonal antibodies to murine anti-human high molecular weight melanoma-associated antigen monoclonal antibodies”, J. Immunol., 143(11):3844-3852 (Dec. 1989).
T. Bumol et al, “Biosynthetic studies of proteoglycans in human melanoma cells with a monoclonal antibody to a core glycoprotein of chondroitin sulfate proteoglycans”, J. Biol. Chem., 259(20):12733-12741 (Oct. 1984).
D. Demetrick et al, “ME491 melanoma-associated glycoprotein family: antigenic identity of ME491, NKI/C-3, neuroglandular antigen (NGA), and CD63 proteins”, J. Natl Cancer Inst, 84(6):422-429 (Mar. 1992).
C. Vennegoor et al, “Circulating melanoma-associated antigen detected by monoclonal antibody NKI/C-3”, Cancer Immunol Immunother, 23:93-100 (1986).
M. Wang et al, “An ocular melanoma-associated a
Ferry Alison L.
Findlay Helen P.
Hahn Susan E.
Young David S. F.
Arius Research Inc.
Canella Karen A.
McHale & Slavin P.A.
Reddig Peter J
LandOfFree
Cytotoxicity mediation of cells evidencing surface... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cytotoxicity mediation of cells evidencing surface..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cytotoxicity mediation of cells evidencing surface... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4021512